All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Yaws is an endemic treponemal disease caused by *Treponema pallidum* subsp *pertenue* \[[@pntd.0004927.ref001]\]. Most cases of yaws are seen in rural communities in tropical countries \[[@pntd.0004927.ref002]\] and are manifest as lesions of the skin, bones and joints. In 2012, single dose azithromycin was shown to be an effective treatment for yaws \[[@pntd.0004927.ref003]\], and mass treatment with azithromycin was subsequently adopted by WHO as the cornerstone of a new yaws eradication campaign \[[@pntd.0004927.ref004]\]. Active yaws is usually seen in children aged 5--14 years, and examination of this age group has been used in many studies to assess the prevalence of active yaws \[[@pntd.0004927.ref005]--[@pntd.0004927.ref007]\]. WHO also recommends surveillance by serology of children aged 1--4 years to determine whether transmission has been interrupted \[[@pntd.0004927.ref004]\].

The Pacific is a particular focus for yaws with a large number of cases reported in Papua New Guinea, the Solomon Islands and Vanuatu \[[@pntd.0004927.ref002]\]. Trachoma, caused by ocular infection with *Chlamydia trachomatis*, is also endemic in the Pacific. As community mass treatment with azithromycin is also central to the control of trachoma \[[@pntd.0004927.ref008]\], there is the potential for synergies between trachoma and yaws programmes in the Pacific \[[@pntd.0004927.ref009]\]. A challenge is the difference in the dose of azithromycin recommended for trachoma (20mg/kg, max 1g) compared to yaws (30mg/kg, max 2g). We previously demonstrated that the prevalence of active and latent yaws declined markedly six months after a single round of mass treatment with azithromycin given as part of a trachoma control program in the Solomon Islands \[[@pntd.0004927.ref010]\], providing the first evidence that low dose azithromycin is an effective intervention to reduce the community prevalence of yaws.

The optimal number and timing of rounds of mass treatment needed to interrupt transmission of yaws are unknown \[[@pntd.0004927.ref011]\], although pilot data from other countries suggest that a single round is inadequate \[[@pntd.0004927.ref007]\]. In 2015 a decision was made not to undertake a second round of azithromycin mass treatment in the Solomon Islands in light of a low reported prevalence of trachomatous trichiasis and a low prevalence of ocular infection with *C*. *trachomatis* \[[@pntd.0004927.ref012]\]. This provided an opportunity to assess any potential rebound in active and latent yaws in the absence of further control measures. It was hoped that these data might inform expansion of yaws control efforts and, in particular, any potential for synergy between yaws and trachoma control programs in the Pacific. We therefore conducted an 18 month follow-up survey to assess whether the seroprevalence of yaws has changed significantly in the absence of any further intervention.

Methods {#sec006}
=======

This survey was conducted 18 months following a single round of azithromycin mass treatment (20mg/kg) conducted by the Solomon Islands Ministry of Health and Medical Services. The study was conducted in the same communities in which we had conducted our previous six month follow-up survey \[[@pntd.0004927.ref010]\]. No further rounds of mass treatment (or any other specific interventions against yaws including case finding surveys and targeted total treatment) had been conducted in these communities since then.

For each household we collected data on the number of residents. We enrolled children aged 1--14 years for assessment, collecting individual level data on age, gender, the presence or absence of clinical signs and symptoms of yaws and yaws treatment history. We categorized skin lesions using the WHO yaws pictorial guide \[[@pntd.0004927.ref013]\]. All data were entered directly into Android smartphones using the ODK software package \[[@pntd.0004927.ref014]\].

For children aged 5--14 years, venepuncture was performed and a serum sample collected. In children aged 1--4 years a finger-prick blood sample was collected onto a filter paper. Filter papers were air-dried and stored in sealed bags with desiccant sachets. From individuals with ulcerative or papillomatous skin lesions, we also collected a swab sample of lesion exudate. Exudate was transferred to a FTA Elute Micro Card (GE Healthcare, Buckinghamshire, UK) using three firm side-to-side motions of the swab across the card. Each card was placed in its own re-sealable plastic packet with an individual desiccant sachet. The samples were transferred to the National Referral Hospital in Honiara, where they were frozen at -20°C, and shipped to the London School of Hygiene & Tropical Medicine (LSHTM), UK, and the Centers for Disease Control and Prevention (CDC), USA, on dry-ice for testing.

Laboratory Testing {#sec007}
------------------

Blood samples were tested at LSHTM. Filter paper samples were eluted and tested using the *Treponema pallidum* particle agglutination test (TPPA, Mast Diagnostics, Merseyside UK) as previously described \[[@pntd.0004927.ref015]\]. For serum samples a TPPA test was performed initially and for samples that were TPPA-positive, a quantitative rapid plasma reagin test (RPR, Deben Diagnostics, Ipswich, UK) was performed.

Lesion swab samples were tested at the CDC using a number of multiplex real-time (RT) PCR assays. Initially samples were tested using an assay for the identification of *T*. *pallidum* subspecies DNA \[[@pntd.0004927.ref005]\]. If the PCR was positive for *T*. *pallidum* subsp. *pertenue* this was followed by a second multiplex RT PCR to detect mutations in the 23S rRNA gene which are associated with azithromycin resistance. All samples were also tested with a duplex RT PCR for the detection of *Haemophilus ducreyi* and *Mycobacterium ulcerans* \[[@pntd.0004927.ref016]\]. All laboratory testing was performed by individuals masked to the clinical findings.

Statistical Analysis {#sec008}
--------------------

In children aged 1--4 years, a positive TPPA was taken as evidence of previous or current yaws infection. For children aged 5--14 years, a positive TPPA was considered as evidence of previous or current yaws infection. We considered individuals with clinical signs of yaws and both a positive TPPA and an RPR titre of ≥1:4 (dual-seropositivity) to have active yaws. We considered individuals who were dual-seropositive but without clinical signs of yaws to have latent yaws. For the purpose of the analysis an RPR titre of ≥1:16 was considered to be a high-titre positive. We classified household size as ≤5 or \>5 residents, 5 householders being the national average according to the most recent census \[[@pntd.0004927.ref017]\]. For each community, we used village level estimates of treatment coverage obtained during our previous six month follow up survey \[[@pntd.0004927.ref010]\]. We classified village level coverage as low (\<80%), high (80--90%) or very high (\>90%). We calculated the prevalence of latent and active yaws in older children (aged 5--14 years) and the sero-prevalence of exposure to yaws in younger children (aged 1--4 years). Logistic regression was used to estimate unadjusted and adjusted odds ratios (ORs) for factors associated with both TPPA- and dual-seropositivity. Robust standard errors were used to calculate all confidence intervals (CIs) and p-values, to account for village-level clustering. All analyses were performed using Stata 13.1 (Statacorp, Texas).

Sample Size {#sec009}
-----------

In our previous follow-up survey, the seroprevalence of yaws infection was 3.6%. We calculated that a sample size of 738 was need to measure a seroprevalence of 4% with a degree of absolute precision of 3%, assuming a design effect of 4.5 (estimated using data from the baseline survey) in children aged 5--14 years. Based on previous pre-MDA data from 5--14 year old children we hypothesized that the seroprevalence amongst children aged 1--4 years would be approximately 1% if transmission had been interrupted following the earlier community mass treatment and 5% if transmission had not been interrupted. We calculated that a sample size of 432 children aged 1--4 years was required to detect a prevalence of 1% with a precision of 2% and a design effect of 4.

Ethical Approval {#sec010}
----------------

Written informed consent was obtained from each participating child's parent or guardian by a member of staff fluent in the local dialect. Assent was obtained from children. Ethical approval for the study was granted by the ethics committees of the Solomon Islands MHMS, the CDC, and LSHTM.

Results {#sec011}
=======

A total of 1,284 children were enrolled from 519 households in 10 communities.

811 children were aged 5--14 years (median 9 years), of whom 401 (49.4%) were male ([Table 1](#pntd.0004927.t001){ref-type="table"}). A serum sample was collected from 770 children (94.9%). Thirty-one children (3.8%) declined collection of a serum sample but assented to collection of a dried-blood spot, whilst 10 children (1.2%) assented to examination but not to sample collection. 473 children aged 1--4 years (median 3 years) were also enrolled, of whom 248 (52.4%) were male. A dried blood spot was collected from 451 children (95.3%) in this age group. Seven children (1.5%) aged under 5 incorrectly had a serum sample (rather than a DBS) collected. No dried blood spot was collected from 15 children aged under 5 (3.2%).

10.1371/journal.pntd.0004927.t001

###### Demographics of study subjects.

![](pntd.0004927.t001){#pntd.0004927.t001g}

  ---------------------------------------------------------- ------------- -------------
  **Number of Children**                                     **1284**      
  **Number of Households**                                   519           
  **Household Size \[Number of residents\] (Median, IQR)**   6 (4--8)      
  **Age \[years\] (Median, IQR)**                            6 (3--10)     
  **Village Level azithromycin Coverage**                    Low (\<80%)   536 (41.7%)
  High (80--90%)                                             501 (39.0%)   
  Very High (\>90%)                                          247 (19.2%)   
  ---------------------------------------------------------- ------------- -------------

Four hundred and thirty seven children (34.0%) had at least one skin lesion. 14 children (1.1%) had lesions considered to be clinically consistent with yaws. The most common non-yaws lesions were scabies and impetigo, as previously reported (A Steer, Personal Communication). As in our initial 6 month follow-up survey, no individual with a skin lesion consistent with yaws had dual-positive serology. Swabs were obtained from nine yaws-like lesions. Swabs could not be obtained from the other three lesions as they were dry/crusted. Of these lesion samples, all were negative on RT-PCR for *T*.*p* subsp *pertenue* and two were positive for *H*. *ducreyi*.

Amongst 5--14 year-old children, 223 had a positive TPPA (27.5%, 95% CI 13.6--47.7%). The TPPA seroprevalence amongst this age group did not differ significantly from either our pre-MDA survey or our initial follow-up survey (31.4% and 25.0% respectively, p\>0.05 for both comparisons). In both the crude and adjusted analyses, only age was associated with TPPA positivity ([Table 2](#pntd.0004927.t002){ref-type="table"}). Thirty-five children had dual positive serology (4.3%, 95% CI 2.1--8.7%), of whom 8 had high-titre positive serology. This did not differ significantly from our initial post-MDA follow-up survey (4.3% vs 3.5%, p = 0.43) but remained significantly lower than our initial pre-MDA survey (4.3% vs 21.7%, p \<0.0001). The level of MDA coverage was strongly associated with dual-seropositivity (p = 0.005). Compared to an MDA coverage above 90%, a village level coverage below 80% was strongly associated with an increased risk of dual-seropositivity (aOR 6.95, 95% CI 1.2--38.3, p = 0.03) ([Table 3](#pntd.0004927.t003){ref-type="table"}). Coverage of between 80--90% was also associated with an increased risk of dual-seropositivity compared to coverage \>90%, but this difference was not statistically significant (aOR 3.99, 95% CI 0.66--24.0, p = 0.12).

10.1371/journal.pntd.0004927.t002

###### Risk factors for TPPA Positivity amongst children aged 5--14 years.

![](pntd.0004927.t002){#pntd.0004927.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                        Indicative Prevalence Data          Unadjusted Odds Ratio\                                   Adjusted Odds Ratio[^\#^](#t002fn002){ref-type="table-fn"}\   p-value
                                                                                                                      (95% CI)                                                 (95% CI)                                                      
  ------------------------------------------------------------------------------- ----------------------------------- -------------------------------------------------------- ------------------------------------------------------------- ---------
  **Age \[years\]**                                                               5-9: 19%                            1.22 [\*](#t002fn001){ref-type="table-fn"} (1.13-1.32)   1.22 (1.13-1.32)                                              \<0.001

                                                                                  10-14: 38.5%                                                                                                                                               

  **Male**                                                                        Male: 28.4%                         1.09 (0.77-1.57)                                         1.19 (0.87-1.63)                                              0.24

                                                                                  Female: 26.6%                                                                                                                                              

  **Household Size \[number of residents\]**                                      ≤5: 30.21%                          1                                                                                                                      

                                                                                  \>5: 25.6%                          0.8 (0.48-1.31)                                          0.75 (0.46-1.23)                                              0.23

  **Village Level azithromycin coverage[^¶^](#t002fn003){ref-type="table-fn"}**   Low Coverage (\<80%): 24.1%         1.13 (0.23-5.48)                                         1.28 (0.26-6.39)                                              0.73

                                                                                  High Coverage (80-90%): 33.4%       1.83 (0.34-10.09)                                        1.96 (0.31-12.56)                                             0.44

                                                                                  Very High Coverage (\>90%): 21.9%   1                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Increased odds associated with each one year increase in age

\# Adjusted for age and gender

¶ Compared to very high coverage (\>90%)

10.1371/journal.pntd.0004927.t003

###### Risk factors for Dual-Seropositivity amongst children aged 5--14 years.

![](pntd.0004927.t003){#pntd.0004927.t003g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                        Indicative Prevalence Data         Unadjusted Odds Ratio\                                  Adjusted Odds Ratio[^\#^](#t003fn002){ref-type="table-fn"}\   p-value
                                                                                                                     (95% CI)                                                (95% CI)                                                      
  ------------------------------------------------------------------------------- ---------------------------------- ------------------------------------------------------- ------------------------------------------------------------- ---------
  **Age \[years\]**                                                               5-9: 3.3%                          1.18[\*](#t003fn001){ref-type="table-fn"} (1.05-1.34)   1.19 (1.08-1.35)                                              0.009

                                                                                  10-14: 5.7%                                                                                                                                              

  **Male**                                                                        Male: 3.2%                         1.77 (0.85-3.71)                                        1.91 (0.93-3.94)                                              0.07

                                                                                  Female: 5.5%                                                                                                                                             

  **Household Size \[number of residents\]**                                      ≤5: 5.7%                           1                                                                                                                     

                                                                                  \>5: 3.3%                          0.57 (0.14-2.32)                                        0.53 (0.13-2.14)                                              0.33

  **Village Level azithromycin coverage[^¶^](#t003fn003){ref-type="table-fn"}**   Low Coverage (\<80%): 6.2%         5.5 (0.97-31.22)                                        6.95 (1.27-38.3)                                              0.03

                                                                                  High Coverage (80-90%): 4.1%       3.6 (0.58-21.67)                                        3.99 (0.66-24.0)                                              0.12

                                                                                  Very High Coverage (\>90%): 1.2%   1                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Increased odds associated with each one year increase in age

\# Adjusted for age and gender

¶ Compared to very high coverage (\>90%)

Amongst children aged 1--4 years, 16 had a positive TPPA (3.5%, 95% CI 1.6--7.1%) including two children aged less than two years (0.9%, 95% CI 0.2--4.0%). This did not differ significantly from the seroprevalence in this age group that had been predicted based on our previous surveys (3.5% vs 5%, p = 0.11). In villages where very high (\>90%) mass treatment coverage was achieved, there were no young children with a positive TPPA, compared to 3.8% and 4.4% TPPA positivity in villages with low (\<80%) and high (80--90%) coverage of mass treatment, respectively, although these differences were not statistically significant (p = 0.08 and 0.06 respectively). Age was the only variable significantly associated with TPPA seropositivity amongst children aged 1--4 years ([Table 4](#pntd.0004927.t004){ref-type="table"}).

10.1371/journal.pntd.0004927.t004

###### Risk factors for TPPA Positivity amongst children aged 1--4.

![](pntd.0004927.t004){#pntd.0004927.t004g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                     Indicative Prevalence Data   Unadjusted Odds Ratio\                                  Adjusted Odds Ratio[^\#^](#t004fn002){ref-type="table-fn"}\   p-value
                                                                            (95% CI)                                                (95% CI)                                                      
  -------------------------------------------- ---------------------------- ------------------------------------------------------- ------------------------------------------------------------- ---------
  **Age \[years\]**                            1-2: 0.87%                   1                                                                                                                     

                                               3-4: 5.8%                    2.21[\*](#t004fn001){ref-type="table-fn"} (1.55-3.15)   2.23 (1.51-3.29)                                              0.001

  **Male**                                     Male: 4.0%                   1.53 (0.58-4.06)                                        1.64 (0.56-4.82)                                              0.33

                                               Female: 2.7%                 1                                                                                                                     

  **Household Size \[number of residents\]**   ≤5: 4.0%                     0.72 (0.25-2.08)                                        0.78 (0.25-2.35)                                              0.62

                                               \>5: 2.9%                    1                                                                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Increased odds associated with each one year increase in age

\# Adjusted for age and gender

Discussion {#sec012}
==========

We have previously demonstrated that a single round of mass treatment with azithromycin at 20mg/kg, given for the purposes of trachoma control, has a significant impact on the prevalence of yaws-like skin lesions and sero-positivity for yaws \[[@pntd.0004927.ref010]\]. In this study we have shown that the benefit appears to extend to 18 months without any further intervention. The WHO yaws eradication strategy \[[@pntd.0004927.ref004]\] suggests that, following initial mass treatment, follow-up surveys with targeted treatment of cases and contacts should take place every 3--6 months. This requirement for at least biannual intervention is a potential barrier to integrating yaws eradication efforts with other NTD control programmes, including trachoma, where annual mass treatment is recommended. The absence of any active cases of yaws in these communities and the lack of a significant change in seroprevalence from 6 to 18 months after mass treatment might suggest that interventions could be spaced at yearly intervals without a significant loss of impact. Consistent with these findings we have previously reported a decline in the number of routinely reported cases of yaws in Western provinces following MDA \[[@pntd.0004927.ref010]\]. In 2013 Western province reported 5,231 cases of yaws and this declined to 3,018 in 2014 and 2,252 cases in 2015. This routine reporting data supports our finding that the impact of MDA has been sustained up to 18 months.

Modelling studies exploring the optimal spacing of MDA are under way, and initial results suggest that such decisions are highly dependent on the basic reproductive number (R~0~) of yaws. Where R~0~ is low (\<1.45) then annually spaced treatment may be sufficient to achieve interruption of transmission (M Marks--Manuscript submitted).

Of particular interest, the village-level treatment coverage was the strongest risk factor for dual-seropositivity 18 months after mass treatment. When the coverage was below 80%, the risk for seropositivity was more than 6 times greater compared to villages where coverage of greater than 90% was achieved. Consistent with these findings in older children, we noted that in villages where very high (\>90%) coverage was achieved there were no seropositive children aged 1--4 years, which may indicate that transmission was interrupted in these communities. Ongoing presumed seroconversion, including in children aged 2 years or less, was documented, however, in villages with coverage below 90%. We cannot exclude the possibility that positive serology in children aged 1--4 years was due to mother-to-child transmission of syphilis. However, in the context of ongoing transmission of yaws amongst older children in these communities, we consider it likely that seropositivity amongst children aged 1--4 years does reflect ongoing transmission of yaws in this age group. These two findings emphasize the need for extremely high coverage during mass treatment. Given the difficulties that can be faced in achieving such high coverage at a programmatic level \[[@pntd.0004927.ref018]\], innovative strategies should be considered to augment yaws eradication efforts. This might include additional school based mass treatment alongside community based approaches, or use of multiple rounds of mass treatment before transitioning to the total targeted treatment phase of the yaws eradication strategy \[[@pntd.0004927.ref004]\].

Our data add to the literature supporting a lower dose of azithromycin (20mg/kg max 1g vs 30mg/kg max 2g) for the treatment of yaws. If a lower dose is proven effective this may help achieve programmatic synergies, especially in the Pacific where several countries have a high prevalence of yaws, and trachoma is also endemic. A WHO sponsored trial (NCT02344628) is being undertaken in Ghana and Papua New Guinea to formally compare the efficacy of these two doses in both active and latent yaws, and it is hoped that this study will provide a definitive answer on the efficacy of the lower dose of azithromycin. The prevalence of ulcers caused by *Haemophilus ducreyi* remained lower than in our pre-MDA study but has not fallen as markedly as that of yaws ulcers. We also noted a large number of ulcers of an unclear aetiology and further studies are required to better understand other causes of ulcers in a post-MDA setting.

The major limitation of our study is the observational design. A study of mass treatment in Papua New Guinea found only 44 serologically confirmed active cases in a total population of 13,166 individuals seen at six months follow-up. Given the smaller sample size of this study, we may have been underpowered to detect rare active cases following the initial round of mass treatment. A larger sample size would also have allowed more precise estimates of the seroprevalence of infection in both age groups but would probably not have altered the major findings of this study.

Our data show that the impact of a single round of mass treatment on yaws prevalence is profound, and appears to last for at least 18 months following mass treatment even in the absence of further interventions. We have demonstrated that mass treatment coverage above 90% is associated with significantly better outcomes than lower coverage. Strategies to improve coverage at all stages of yaws eradication efforts should be investigated.
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